Can You Take Weight Loss Injections with Methotrexate?

Does methotrexate prevent you from using a GLP-1 weight loss injection?

The short answer is: not automatically. There is no licence-level contraindication that places methotrexate and GLP-1 receptor agonists in a category that rules out combined use entirely. That said, "not automatically ruled out" is a long way from "straightforward". A question our prescribers hear most weeks is some version of this, usually from someone managing rheumatoid arthritis or psoriasis who has been told by a rheumatologist that weight loss would actually help their condition, and who is now trying to work out whether the two treatments can coexist.

The answer sits with a prescriber who can see the full picture: your current methotrexate dose, how well it is tolerated, your liver function history, any folate supplementation you take, and the broader medication list. GLP-1 medicines slow gastric emptying, the rate at which food and oral medicines leave the stomach. For most drugs this has little practical consequence, but for something like methotrexate, where absorption and timing matter, the interaction warrants a considered clinical discussion rather than a simple yes or no. The general eligibility criteria for weight loss injections give you a useful starting point, but individual cases need individual review.

If you are on weekly oral methotrexate, let the prescribing team know explicitly. If you inject methotrexate rather than taking it orally, the gastric-emptying concern is less directly relevant, though your full health context still applies. Either way, transparency about your existing treatment is non-negotiable.

What specific risks does the combination of GLP-1 medicines and methotrexate raise?

Two areas deserve particular attention. The first is liver health. Methotrexate requires regular monitoring of liver enzymes because long-term use carries a risk of hepatotoxicity, particularly at higher cumulative doses. GLP-1 receptor agonists are not typically hepatotoxic, but any medicine in a complex regimen adds a variable, and a prescriber managing both will want a current picture of your liver function before proceeding. Weight loss itself, especially significant weight loss, can also temporarily alter liver enzyme readings, so the monitoring picture gets busier.

The second area is gastrointestinal side effects. Methotrexate frequently causes nausea, reduced appetite and sometimes vomiting, particularly around the day of the dose. GLP-1 medicines (especially in the early weeks of treatment or following a dose increase) produce a similar GI profile. The NHS medicines guidance on tirzepatide notes nausea as one of the most commonly reported side effects, and the pattern is comparable for semaglutide. Running these two GI burdens in parallel can make tolerability harder to manage, and harder to attribute: if nausea worsens, knowing whether it is the methotrexate, the GLP-1 medicine, or the combination matters for how the prescriber responds.

For a fuller account of what the GI side-effect pattern looks like on these medicines, the weight loss injections overview covers the clinical trial picture in plain language. It is worth reading before any consultation, so you can describe your own GI baseline accurately.

How should you approach the prescribing conversation if you are on methotrexate?

Start with whoever manages your methotrexate, whether that is a rheumatologist, dermatologist or GP. Ask specifically whether they have any concerns about adding a GLP-1 receptor agonist given your current dose, liver monitoring status and disease control. Bring that context to your weight loss consultation. A responsible prescribing service will ask about your full medication list; if one does not, that is itself a red flag about the level of clinical review on offer.

The GPhC register at pharmacyregulation.org/registers lets you check that any online pharmacy is properly registered before sharing personal health information. Every prescription at a regulated service goes through clinical review, not a checkbox, but an actual assessment of your profile. For people on complex medication regimens, that review is the point, not a formality.

It is also worth asking about the duration of treatment. How long weight loss injections are used depends on clinical response and ongoing review; for someone on methotrexate long-term, the prescriber needs to build that monitoring rhythm into the broader picture from the start.

If you have questions about how the consultation process works, the FAQs cover the typical steps in plain terms. When you are ready to talk to a prescriber, checking your eligibility starts a free clinical consultation with a GPhC-registered Independent Prescriber who reviews every application the same day.

Is there anything about weight loss itself that could affect your methotrexate management?

Yes, and this is often the part people do not think to mention to their rheumatologist or dermatologist. Significant weight loss changes body composition in ways that can affect how methotrexate distributes and accumulates. Some prescribers adjust methotrexate dose thresholds as weight changes substantially. There is also emerging evidence, referenced in clinical obesity guidelines from NICE's overweight and obesity management guideline (NG246), that excess body weight drives systemic inflammation, the same inflammation that conditions like rheumatoid arthritis thrive on. Weight loss may, over time, improve disease control in a way that affects what dose of methotrexate you need. That is a conversation for your specialist, but it is a genuinely useful one to have before starting, not months in.

People managing weight alongside inflammatory conditions have particular reasons to think carefully about who weight loss injections are suitable for and to bring their full clinical history to the table, including whether any coexisting conditions such as gallstones may be relevant, which is something you can read about in our guide covering weight loss injections and gallstones. The upside of doing this properly is that the two treatment aims, managing inflammation and managing weight, may end up working in the same direction.